27 November 2023
Pharma C Investments PLC
("Pharma C" or the "Company")
Publication of Circular and Notice of General Meeting
Pharma C (AQSE: PCIL) announces that a general meeting of the Company ("GM") will be held at 11 am on 11 December 2023 at the offices of Hill Dickinson LLP, The Broadgate Tower, 20 Primrose St, London EC2A 2EW. The formal notice of the General Meeting has been posted to all shareholders and is available to download from the Company's website www.pharmacinvestments.com
The purpose of the General Meeting is to propose four resolutions that require shareholder approval.
Ordinary resolutions
Resolution 1: amend the Company's investment policy to allow the Company to consider investments or businesses in the technology, fintech and AI sectors;
Resolution 2: the Directors be generally and unconditionally authorised to exercise all the powers of the Company to allot new ordinary shares of £0.0001 each in the Company (including any rights to subscribe for or convert into such new ordinary shares) up to an aggregate nominal value of £2,281,000;
Special resolutions
Resolution 3: that each existing ordinary share of £0.0025 in the capital of the Company (each an "Existing Ordinary Share") be sub-divided and converted into one ordinary share of £0.0001 and one deferred share of £0.0024 in the capital of the Company.
Resolution 4: that conditional upon the passing of Resolutions 2 and 3, the Directors be empowered to allot equity securities for cash pursuant to the authority conferred by Resolution 2 above as if section 561 of the Companies Act and any pre-emption rights in the Articles did not apply to such allotment.
The Directors of Pharma C take responsibility for this announcement.
For further information please visit www.pharmacinvestments.com
Pharma C Investments |
|
Gavin Sathianathan, Investment Strategy Director |
|
First Sentinel Corporate Finance |
|
Brian Stockbridge, Corporate Adviser |
+44 20 3855 5551 |